# Cleveland Clinic

> Cleveland Clinic is a VC fund in Cleveland backing Health Care and Medical. See 26 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cleveland, United States
- Total investments: 26
- Last investment: Jan 2026
- Lead investor: 27%
- Fund size: $7.5M
- Last fund: May 2016
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/cleveland-clinic
- X (Twitter): http://twitter.com/ClevelandClinic
- Website: http://my.clevelandclinic.org
- Facebook: http://www.facebook.com/ClevelandClinic/info

Cleveland Clinic is a non-profit academic medical center that integrates clinical and hospital care with research and education. Its mission is to provide better care for the sick, investigate their problems, and further the education of those who serve.

## Contacts

5 contacts available for Cleveland Clinic. Shizune tracks 15 team members at Cleveland Clinic. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/cleveland-clinic?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 13 | 50% |
| Medical | 6 | 23% |
| Therapeutics | 5 | 19% |
| Biotechnology | 4 | 15% |
| Medical Device | 4 | 15% |

27 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 9 | 35% |
| Series B | 5 | 19% |
| Funding Round | 3 | 12% |
| Seed | 2 | 8% |
| Series C | 1 | 4% |

8 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Akhil Saklecha | Managing Director | 3 | https://shizune.co/investors/profile/akhil-saklecha |
| Dennis L. Laraway | Chief Financial Officer | 1 | https://shizune.co/investors/profile/dennis-l-laraway |
| Joseph Nally | Nephrologist | 0 | https://shizune.co/investors/profile/joseph-nally |
| Pamela Miller | Chairman of the Board of Directors | 0 | https://shizune.co/investors/profile/pamela-miller |
| Samuel Miller | Member of the Board of Directors | 0 | https://shizune.co/investors/profile/samuel-miller-3 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Enspire DBS Therapy | Enspire DBS Therapy supports stroke recovery patients using deep brain stimulation with physical rehabilitation to restore motor function. Enspire DBS offers a robust method to mediate the effects of stimulation and stroke rehabilitation. | $10.3M | Series B | Jan 13, 2026 |  |
| Mediview XR | MediView AR, LLC is a startup Ohio based medical device company that has designed and patented intellectual property in development of Extended Reality Surgical Navigation with intended use in ablation and biopsy of cancerous tumors. | $24M | Series A | Oct 06, 2025 |  |
| Method AI | Method AI is developing an AI-backed surgical navigation platform to drive improved patient outcomes for robotic surgical oncology procedures. | $20M | Series A | Aug 21, 2025 |  |
| Method AI | Method AI is developing an AI-backed surgical navigation platform to drive improved patient outcomes for robotic surgical oncology procedures. The company’s product will leverage deep tissue imaging and machine learning algorithms to provide physicians with real-time guidance against a best outcome surgical plan. | $20M | Series A | Aug 21, 2025 |  |
| 1m | 1m is a healthtech company that offers a software platform for risk management and performance improvement services. | $7.3M | Series A | Dec 12, 2024 |  |
| 1m | 1m is a healthtech company that offers a software platform for risk management and performance improvement services. | $7.3M | Series A | Dec 12, 2024 |  |
| XII Medical | XII Medical is a medical device developer company. It develops a minimally invasive outpatient technology for the treatment of obstructive sleep apnea. | $45M | Series B | Aug 21, 2024 |  |
| Strolll | Strolll Neurotechnology | $3M | Corporate Round | Aug 20, 2024 |  |
| Neuro Therapia | NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain.Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016. | $12.3M | Series B | Aug 06, 2024 |  |
| Neuro Therapia | NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain.Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016. | $12.3M | Series B | Aug 06, 2024 |  |

10 of 26 investments shown.

## Co-investors
- [JobsOhio](https://shizune.co/investors/profile/jobsohio) — VC Fund, 9 deals together
- [Banner Health](https://shizune.co/investors/profile/banner-health) — VC Fund, 4 deals together
- [GE Healthcare](https://shizune.co/investors/profile/ge-healthcare) — VC Fund, 4 deals together
- [Alzheimer's Drug Discovery Foundation](https://shizune.co/investors/profile/alzheimers-drug-discovery-foundation) — VC Fund, 3 deals together
- [Brain Trust Accelerator Fund](https://shizune.co/investors/profile/brain-trust-accelerator-fund) — VC Fund, 3 deals together
- [Dolby Family Ventures](https://shizune.co/investors/profile/dolby-family-ventures) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Cleveland Clinic invest in?

Cleveland Clinic invests primarily in Health Care, Medical and Therapeutics startups, most often at Series A and Series B stage. Most of the 26 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Cleveland Clinic?

Public channels for Cleveland Clinic include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Cleveland Clinic?

The team at Cleveland Clinic includes Akhil Saklecha (Managing Director), Dennis L. Laraway (Chief Financial Officer) and Joseph Nally (Nephrologist), among 15 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co